TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who had failed H.pylori eradication therapies before.~2. Age between 18\~70, both gender.~3. Patients who had failed H.pylori eradication therapies during last 2 years and stop the eradication therapies for at least 2 months.~4. Women are eligible if they are not pregnant or nursing, and if they are of childbearing potential they are required to use medically acceptable contraception for the duration of the study and 30 days thereafter.~Exclusion Criteria:~1. Patients are excluded if they have previously used tetracycline and furazolidone antibiotics to eradicate infection with H. pylori.~2. Contraindications to study drugs.~3. Substantial organ impairment, severe or unstable cardiopulmonary or endocrine disease.~4. Constant use of anti-ulcer drugs ( including taking proton-pump. inhibitors(PPI) within 2 weeks before the \[13C\] urea breath test), antibiotics or bismuth complexes (more than 3 times /1 month before screening).~5. Pregnant or lactating women.~6. Underwent upper gastrointestinal Surgery.~7. Patients with Barrett esophageal or highly atypical hyperplasia, have symptom of dysphagia.~8. Evidence of bleeding or iron efficiency anemia.~9. A history of malignancy.~10. Drug or alcohol abuse history in the past 1 year.~11. Systemic use of corticosteroids, non steroidal anti-inflammatory drugs, anticoagulants, platelet aggregation inhibitors (except the use of aspirin for less than 100 mg/d).~12. Enrolled in other clinical trials in the past 3 months.~13. Patients who has psychological problem or poor compliance.~14. Refuse to sign informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- berberine plus amoxicillin quadruple therapy (Type: EXPERIMENTAL): Berberine 500mg three time daily for 14days, amoxicillin 1000 mg, esomeprazole 20 mg, and Bismuth 200mg by mouth, twice daily for 14 days.
- tetracycline plus furazolidone quadruple therapy (Type: ACTIVE_COMPARATOR): Tetracycline 500mg three time daily for 14days，furazolidone 100 mg, esomeprazole 20 mg, and Bismuth 200mg by mouth, twice daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Select Inclusion Criteria:~1. Documented histological or cytological diagnosis of renal cell cancer with a clear-cell component.~2. Measurable disease as determined by the investigator.~3. Must have received at least one VEGFR-targeting TKI (eg, sorafenib, sunitinib, axitinib, pazopanib or tivozanib).~4. Recovery from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.~5. Adequate organ and marrow function.~6. Sexually active fertile subjects(male and female)must agree to use medically accepted methods of contraception during the course of the study and for 4 months after the last dose of study treatment.~7. Female subjects of childbearing potential must not be pregnant at screening.~Select Exclusion Criteria:~1. Prior treatment with everolimus, or any other specific or selective TORC1/PI3K/AKT inhibitor (eg, temsirolimus), or cabozantinib.~2. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before randomization.~3. Receipt of any type of anticancer antibody (including investigational antibody) within 4 weeks before randomization.~4. Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before randomization. Systemic treatment with radionuclides within 6 weeks before randomization. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.~5. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least 3 months before randomization.~6. Concomitant anticoagulation at therapeutic doses with oral anticoagulants or platelet inhibitors.~7. Chronic treatment with corticosteroids or other immunosuppressive agents.~8. Serious illness other than cancer.~9. Major surgery within 3 months before randomization. Complete wound healing from major surgery must have occurred 1 month before randomization and from minor surgery at least 10 days before randomization.~10. Pregnant or lactating females.~11. Diagnosis of another malignancy within 2 years before randomization, except for superficial skin cancers, or localized, low grade tumors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cabozantinib (XL184) (Type: EXPERIMENTAL): Cabozantinib (XL184) 60 mg tablet once daily.
- Everolimus (Afinitor) (Type: ACTIVE_COMPARATOR): Everolimus (Afinitor) 10 mg tablet once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cortisone Injection vs Trigger Point Dry Needling Fin the Treatment of Greater Trochanter Pain Syndrome: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18+ years old~* lateral hip pain (anywhere from iliac crest to mid ITB)~* active email account~Exclusion Criteria:~* low back pain associated with the hip pain~* motor and/or sensory impairment consistent with radiculopathy~* active infection/malignancy of the hip~* connective tissue disease~* pregnancy~* non-English speaking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cortisone Injection (Type: ACTIVE_COMPARATOR): Fifty patients with GTPS will be randomized into a CI or TDN group. Treatment will be carried out at the 1st visit following consent according to SOC. Treatment will be administered according to standard of care for up to 6 weeks.
- Trigger Point Dry Needling (Type: ACTIVE_COMPARATOR): Fifty patients with GTPS will be randomized into a CI or TDN group. Treatment will be carried out at the 1st visit following consent according to SOC. Treatment will be administered according to standard of care for up to 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 85 years~* History of, or at high risk for, cardiovascular disease (CVD) including coronary artery disease, symptomatic peripheral arterial disease, cerebrovascular atherosclerotic disease, or at high risk for a cardiovascular event~* Participant-reported SI due to an adverse safety effect that started or increased during statin therapy and resolved or improved when statin therapy was discontinued resulting in an inability to tolerate:~  * 2 or more statins at any dose, or~ * 1 statin at any dose and unwilling to attempt a second statin or advised by a physician to not attempt a second statin.~Please note that participants currently tolerating very low dose statin therapy (an average daily dose of rosuvastatin \<5 mg, atorvastatin \<10 mg, simvastatin \<10 mg, lovastatin \<20 mg, pravastatin \<40 mg, fluvastatin \<40 mg, or pitavastatin \<2 mg) are considered to be intolerant to that low dose statin. Patients may continue taking very low dose statin therapy throughout the study provided that it is stable (used for at least 4 weeks prior to screening) and well tolerated.~* Written confirmation by both participant and investigator that the participant is statin intolerant as defined above, aware of the benefit of statin use to reduce the risk of MACE including death, and also aware that many other participants who are unable to tolerate a statin are able to tolerate a different statin or dose.~* Men and nonpregnant, nonlactating women~* Fasting blood LDL-cholesterol ≥ 100 (2.6 mmol/L) at screening~Exclusion Criteria:~* Fasting blood triglycerides greater than 500 mg/dL (5.6 mmol/L) at screening~* Recent (within 90 days of screening) history of major cardiovascular events, transient ischemic attack (TIA), or unstable or symptomatic cardiac arrhythmia~* History of severe heart failure~* Uncontrolled hypertension or uncontrolled diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Bempedoic Acid 180 mg (Type: EXPERIMENTAL): Bempedoic acid 180 mg tablet taken orally, once daily.
- Placebo Comparator (Type: PLACEBO_COMPARATOR): Matching placebo tablet taken orally, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Antimalarial Drugs Used in Pregnancy in Tanzania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~A pregnant woman who has either a positive blood smear for P.falciparum with at least 1000 asexual parasites/uL in an asymptomatic woman~or any of the following symptoms within 2 days prior to consultation:~* history of fever;~* headache,~* vomiting,~* chills/rigors,~* and/or any of the following signs: temperature \>37.50C and \<39.50C, Hb\>5 and \<9 g/dl together with P.falciparum parasitaemia at any density~and (in both cases) the following:~1. Has no exclusion criterion (see below);~2. Is 14-34 weeks pregnant on the day of attending the ANC clinic or OPD;~3. Has a viable foetus, defined by presence of foetal heartbeat by sonicaid or pinnard (foetal heartbeat is not heard until 14 weeks);~4. Is able to take study drugs by the oral route;~5. Is able to attend stipulated days for follow up clinic and provide specimens;~6. Gives informed written or witnessed verbal consent to participate by herself, and also through her parent/guardian if aged \<15 years (in conformity to Tanzania Law).~Exclusion Criteria:~1. Severe and complicated forms of malaria (as defined by WHO, 1996);~2. Pregnancy in the first trimester;~3. A mixed plasmodial infection;~4. Complicated pregnancy, e.g. signs/symptoms of toxaemia of pregnancy;~5. 23 or more abortions or stillbirths;~6. Presence of concomitant disease masking assessment of the response to treatment ;~7. An intake of drugs contraindicated in pregnancy, e.g. tetracycline, cotrimoxazole or a macrolide antibiotic;~8. An intake of drugs with effective antimalarial activity within the last 2 weeks.~9. Significantly abnormal baseline haematology (except anaemia) or clinical chemistry parameters, e.g. laboratory evidence of renal impairment (serum creatinine \>2 mg/dl) or of hepatitis (alanine aminotransferase \[ALT\] \>5 times upper limit of normal);~10. Previous participation in the study: Women having a second episode of malaria after completing the 28-day follow up will have details recorded and offered quinine but not be re-enrolled.~11. Multiple gestation pregnancies, eg twins~12. Mother aged 38 years or above

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CUTE (Chronic Urticaria Treatment Evaluation)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- At visit 1: Clinical history of Chronic Idiopathic Urticaria for a period of at least 6 weeks during the last 3 months without an identifiable cause~- At visit 2 (after a baseline period of at least 3 days): patient with adequate signs of CIU, both in terms of symptoms and severity.~Exclusion Criteria:~- Any condition that would interfere with the evaluation of the therapeutic response.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levocetirizine (Type: EXPERIMENTAL): Levocetirizine, once daily, 4 week duration
- Desloratadine (Type: ACTIVE_COMPARATOR): Desloratadine, once daily, 4 week duration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telmisartan and Hydrochlorothiazide Antihypertensive Treatment Study in High Sodium Intake Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age≥18~* Essential hypertension: systolic blood pressure (SBP) is between 140mmHg-179mmHg and diastolic blood pressure (DBP)\<110mmHg OR DBP is between 90mmHg-109mmHg and SBP\<180mmHg.~* Hypertension patients diagnosed by spot urine test (urine sodium≥200mmol/24h).~* Subjects are not using antihypertensive medicines or medicines which affect the blood pressure within a week.~* Subjects volunteer to be brought in the research and have signed informed consent form, given that they have understood the research content.~Exclusion Criteria:~* Females who are already pregnant, in lactation and intend to be pregnant.~* Patients who have seriously allergic reaction or angioneurotic edema when taking ARB; Patients who have allergic history of thiazide diuretic (HCTZ) or sulfonamides.~* Patients who do not want to stop or have to take the medicines which are also antihypertensive or affect the blood pressure, other than which provided by the research.~* Stroke or CHD patients who are diagnosed within 6 months. CHD patients are identified by being diagnosed by coronary arteriography or coronary CT angiography, having received coronary stent or coronary artery bypass surgery, or being diagnosed with acute myocardial infarction. Stroke patients are identified by being diagnosed with cerebral thrombosis, cerebral embolism, cerebral hemorrhage, subarachnoid hemorrhage or transient ischemic attack.~* Patients who are clearly diagnosed with following diseases: Congenital disease, myocardiopathy, serious arrhythmia, pulmonary heart disease, various of cardiac failure.~* Patients who are clearly diagnosed with following symptoms or diseases: Proteinuria or heavy proteinuria, renal insufficiency or serious renal function damage, hepatic insufficiency or serious hepatic function damage; retinal exudates or hemorrhage, or papilledema.~* Patients who are clearly diagnosed with serious or deadly diseases in other systems.~* Patients who get dementia or other serious diseases cannot cooperate with researchers.~* Patients who drink 200g white spirits per day in past week.~* Patients who meet other situations which are considered to be inappropriate to be enrolled into the study by researchers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telmisartan (Type: EXPERIMENTAL): capsule,40mg per day,2 months
- Hydrochlorothiazide (Type: EXPERIMENTAL): tablet, 25mg per day, 2 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ages 18-80~2. Male and female subjects of all races and ethnicities including Spanish speaking subjects~3. Cirrhosis of any cause~4. Any grade of hepatic encephalopathy (1-4)~5. A legally authorized representative has to be able and willing to comply with all protocol procedures and to understand, sign and date an informed consent document, and authorize access to protected health information on the subjects behalf~Exclusion Criteria:~1. Acute liver failure~2. Structural brain lesions (as indicated by computed tomography imaging if available and confirmed by neurological exam)~3. Other causes of altered mental status (i.e. not meeting the definition of hepatic encephalopathy)~4. Previous use of rifaximin or neomycin in past 7 days~5. Prisoners~6. Pregnancy~7. \<18 years old~8. Serum sodium \<125 mEq/L~9. Receiving \> 1 dose of lactulose prior to enrollment~10. Uncontrolled infection with hemodynamic instability requiring vasopressors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Polyethylene glycol 3350-electrolyte solution (GoLYTELY®) (Type: ACTIVE_COMPARATOR): None
- Lactulose (Type: OTHER): Per standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of LAPS-Exendin on Body Weight in Obese Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
1. Inclusion Criteria:~   * Age: 18 years to 65 years~  * Genders: male and female~  * healthy obese population~  * non-diabetes~  * stable body weight for at least 3 months prior to screening~2. Exclusion Criteria~   * Pregnant or nursing (lactating) women~  * Drug-induced obesity~  * Diabetes mellitus (type 1, 2, and other)~  * Previous surgical treatment for obesity~  * Any known history of severe gastrointestinal (GI) disease or intolerance~  * Known history of pancreatitis with presence of raised serum amylase and lipase~  * History of suicide attempts or recent history (within 2 years prior to screening) of major depression, anxiety, or other psychiatric disease requiring treatment with prescription medication including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitor s (SNRIs), antipsychotics, and lithium.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- HM11260C (Type: EXPERIMENTAL): HM11260C 4 mg weekly sc injection
- Placebo (Type: PLACEBO_COMPARATOR): Placebo weekly sc injection
- HM11260C 6 mg/week (Type: EXPERIMENTAL): HM11260C 6 mg weekly sc injection
- HM11260C 6 mg/biweekly (Type: EXPERIMENTAL): HM11260C 6 mg biweekly sc injection
- HM11260C 8 mg/biweekly (Type: EXPERIMENTAL): HM11260C 8 mg biweekly sc injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ranitidin Versus Omeprazole in Patients Taking Clopidogrel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years old~* Coronary artery disease, defined as previous myocardial infarction and/or coronary angioplasty and/or CABG surgery and/or coronariography showing obstruction of at least 50 % in one of major epicardial vessels~* Treatment with Acetylsalicylic Acid (ASA) 100 mg/day~Exclusion Criteria:~* Use on the last 7 days of any other antiplatelet drug beside ASA or oral anticoagulant~* Previous utilization of PPI or ranitidine in the last 7 days before randomization~* Any active bleeding~* Pregnancy or woman of childbearing age without contraceptive method~* Hemoglobin \< 10 g/dL or hematocrit \< 30 %, hematocrit \> 50 %, platelets \< 100.000/mm3 or \> 500.000/mm3; creatinin clearance \< 50 ml/minute~* Percutaneous coronary intervention (PCI) on the last 30 days before randomization (or PCI on the last year when drug-eluted stents are used); CABG surgery on the last 90 days; acute coronary syndrome on the last 60 days~* Active malignant neoplasm~* Active peptic ulcer disease on the last 60 days or upper gastrointestinal bleeding any time in life~* Known allergy to the drugs clopidogrel, ranitidine or omeprazole~* Refuse to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- omeprazole (Type: EXPERIMENTAL): Omeprazole 20 mg (oral route) twice a day will be given to the subjects for one week. This intervention will be compared with ranitidin 150 mg (oral route) twice a day.
- ranitidine (Type: EXPERIMENTAL): Ranitidine 150 mg (oral route) twice a day will be given to the subjects for one week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is in good health with the exception of mild to moderate hypertension~* Patient is willing to comply with the study restrictions~* Patient does not smoke~Exclusion Criteria:~* Patient has a history of any illness that might confound the results of the study or make participation in the study unsafe~* Patient is taking a prescription medication that is contraindicated for use with COZAAR® or IMDUR®~* Patient has a condition for which there is a warning, contraindication, or precaution against the use of COZAAR® or IMDUR®

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): losartan 100 mg
- 2 (Type: ACTIVE_COMPARATOR): ISMN 60 mg
- 3 (Type: ACTIVE_COMPARATOR): losartan 100 mg + ISMN 15 mg
- 4 (Type: ACTIVE_COMPARATOR): losartan 100 mg + ISMN 60 mg
- 5 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete